Development and Validation of the Asian AMD Age-Related Macular Degeneration Risk Scale
DOI:
https://doi.org/10.56294/saludcyt2025537Keywords:
macular degeneration, eye diseases, risk factors, perceived social supportAbstract
Introduction: This study aimed to develop a method for predicting the risk of developing macular degeneration in the early stages by facilitating prompt intervention by medical professionals.
Methods: Using a cross-sectional design, 455 age-related macular degeneration (AMD) patients from Kazakhstan were recruited via random sampling. Demographic traits, familial AMD history, medical history, and eye-related characteristics were collected through a systematic questionnaire. The patient cohort comprised 169 Caucasians and 286 Asians, with 160 males and 295 females.
Results: Notably, 117 individuals (25.7%) were classified as high AMD risk, 322 (70.8%) as moderate risk, and 16 (3.5%) as low risk. Additionally, eye-related findings revealed high-risk factors, including bright iris colors, increased UV exposure, and cataract surgery, alongside presbyopia and myopia. The study underscores the need for national/regional AMD risk stratification to inform monitoring and screening programs. Recognizing high-risk individuals holds paramount significance from both public health and therapeutic perspectives, offering opportunities for early detection and management to mitigate permanent vision loss.
Conclusions: The findings elucidate the interplay between risk factors, shedding light on their collective impact on AMD risk. Overall, this study's predictive model and risk categorization framework have substantial implications for ophthalmological practice, enabling timely preventive measures and potentially revolutionizing AMD management.
References
1. Cheung CMG, Laude A, Yeo I, Tan S-P, Fan Q, Mathur R, et al. Systemic, ocular and genetic risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in Singaporeans. Scientific reports. 2017;7(1):1-10.
2. Colijn JM, Buitendijk GH, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, et al. Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology. 2017;124(12):1753-63.
3. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacological reports. 2006;58(3):353.
4. Curcio CA, Medeiros NE, Millican CL. Photoreceptor loss in age-related macular degeneration. Investigative ophthalmology & visual science. 1996;37(7):1236-49.
5. Group A-REDSR. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of ophthalmology. 2001;119(10):1417-36.
6. Suieubekov B, Yeshmanova A. New research and changing paradigms of coagulopathy in children after cardiac surgery: A narrative review. Futurity Medicine. 2022;1(1):27-34.
7. Kustryn T, Nasinnyk I, Nevskaya A, Zadorozhnyy O, Korol A. Changes in structural and functional retinal features resulting from the effect of a long-acting steroid in serous PED associated with AMD: a 36-month follow-up study. Oftalmol Zh. 2016;5:28-34.
8. Fedchenko S, Zadorozhnyy O, Korol A. Efficacy of 577-nm retinal pigment epithelium laser photocoagulation in age-related maculopathy patients with various extents of morphological and functional loss. Journal of Ophthalmology (Ukraine). 2017(5):478.
9. Ismayilova I, Turdaliyeva B, Aldasheva N, Veselovskaya N. Assessing the quality of life in age-related macular degeneration patients: A cross-sectional study in Kazakhstan. Acta Bio Medica: Atenei Parmensis. 2022;93(6).
10. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine. 2006;355(14):1432-44.
11. Chakravarthy U, Lim JI. New treatments for neovascular acute macular degeneration. British Medical Journal Publishing Group; 2007. p. 269-70.
12. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine. 2006;355(14):1419-31.
13. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. The Lancet. 2007;370(9583):204-6.
14. Alimukhamedov U. Acute renal failure in newborns in the practice of a pediatrician of the future. Futurity Medicine. 2022;1(4):17-24.
15. Khalid N. The role of artificial intelligence in the management of lung cancer: a narrative review. Futurity Medicine. 2023;2(1):36-46.
16. Krishnadev N, Meleth AD, Chew EY. Nutritional supplements for age-related macular degeneration. Current opinion in ophthalmology. 2010;21(3):184.
17. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration. Cochrane Database of Systematic Reviews. 2017(7).
18. Sepbayeva A. Tactics of managing children-patients with post-coagulopathy cardiac surgery interventions. Futurity Medicine. 2022;1(4):34-43.
19. Romanelli F, Stolfa S, Ronga L, Del Prete R, Bavaro D, Saracino A, et al. Coinfections in intensive care units. Has anything changed with Covid-19 pandemia? Acta Biomed. 2023;94(3):2.
20. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98(7):1128-34.
21. Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health. 2014;2(2):e106-e16.
22. Heesterbeek TJ, Lorés‐Motta L, Hoyng CB, Lechanteur YT, den Hollander AI. Risk factors for progression of age‐related macular degeneration. Ophthalmic and Physiological Optics. 2020;40(2):140-70.
23. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Age-related macular degeneration preferred practice pattern®. Ophthalmology. 2020;127(1):P1-P65.
24. Flaxman SR, Bourne RR, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. The Lancet Global Health. 2017;5(12):e1221-e34.
25. Delcourt C, Souied E, Sanchez A, Bandello F. Development and validation of a risk score for age-related macular degeneration: the STARS Questionnaire. Investigative Ophthalmology & Visual Science. 2017;58(14):6399-407.
26. Kulik A, Bogomolov A. Method for predicting the risk of macular degenera‑tion. Medical News of North Caucasus= Medicinskij vestnik Severnogo Kavkaza. 2016;11(3):448-5.
27. Rizaev JA, Yangieva NR, Lokes KP. Development of a method for predicting the risk of occurrence and early detection of agerelated macular degeneration of the retina. Bull Probl Biol Med. 2020;1(1):260.
28. Ferris FL, Davis MD, Clemons TE, Lee L-Y, Chew EY, Lindblad AS, et al. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Archives of ophthalmology (Chicago, Ill: 1960). 2005;123(11):1570-4.
29. Seddon JM, Reynolds R, Yu Y, Daly MJ, Rosner B. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology. 2011;118(11):2203-11.
30. Klein R, Klein BE, Knudtson MD, Wong TY, Cotch MF, Liu K, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology. 2006;113(3):373-80.
31. Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology. 2007;114(6):1143-50.
32. Wong TY, Tikellis G, Sun C, Klein R, Couper DJ, Sharrett AR. Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Ophthalmology. 2007;114(1):86-91.
33. Hogg RE, Woodside JV, Gilchrist SE, Graydon R, Fletcher AE, Chan W, et al. Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology. 2008;115(6):1046-52. e2.
34. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2003;110(4):636-43.
35. Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology. 2012;119(3):571-80.
36. Buch H, Nielsen NV, Vinding T, Jensen GB, Prause JU, la Cour M. 14-year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study. Ophthalmology. 2005;112(5):787-98.
37. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC ophthalmology. 2010;10:1-13.
38. Tomany SC, Wang JJ, Van Leeuwen R, Klein R, Mitchell P, Vingerling JR, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology. 2004;111(7):1280-7.
39. Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review. Clinical interventions in aging. 2017:1313-30.
40. Park S, Lee J, Woo S, Ahn J, Shin J, Song S, et al. Epidemiologic survey committee of the Korean ophthalmologic society. Age-related macular degeneration: prevalence and risk factors from Korean national health and nutrition examination survey, 2008 through 2011. Ophthalmology. 2014;121(9):1756-65.
41. Zapata MA, Burés A, Gallego-Pinazo R, Gutiérrez-Sánchez E, Oléñik A, Pastor S, et al. Prevalence of age-related macular degeneration among optometric telemedicine users in Spain: a retrospective nationwide population-based study. Graefe's Archive for Clinical and Experimental Ophthalmology. 2021;259:1993-2003.
42. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102(2):205-10.
43. Maller J, George S, Purcell S, Fagerness J, Altshuler D, Daly MJ, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nature genetics. 2006;38(9):1055-9.
44. Smith W, Mitchell P. Family history and age‐related maculopathy: the Blue Mountains Eye Study. Australian and New Zealand journal of ophthalmology. 1998;26(3):203-6.
45. Saunier V, Merle BM, Delyfer M-N, Cougnard-Grégoire A, Rougier M-B, Amouyel P, et al. Incidence of and risk factors associated with age-related macular degeneration: four-year follow-up from the ALIENOR study. JAMA ophthalmology. 2018;136(5):473-81.
46. Thornton J, Edwards R, Mitchell P, Harrison R, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye. 2005;19(9):935-44.
47. Chakravarthy U, Augood C, Bentham G, de Jong P, Rahu M, Seland J, et al. Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology. 2007;114(6):1157-63.
48. Delcourt C, Diaz J-L, Ponton-Sanchez A, Papoz L, Group PS. Smoking and age-related macular degeneration: the POLA Study. Archives of Ophthalmology. 1998;116(8):1031-5.
49. Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. Jama. 1996;276(14):1147-51.
50. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. Jama. 1996;276(14):1141-6.
51. Solberg Y, Rosner M, Belkin M. The association between cigarette smoking and ocular diseases. Survey of ophthalmology. 1998;42(6):535-47.
52. Jonasson F, Fisher DE, Eiriksdottir G, Sigurdsson S, Klein R, Launer LJ, et al. Five-year incidence, progression, and risk factors for age-related macular degeneration: the age, gene/environment susceptibility study. Ophthalmology. 2014;121(9):1766-72.
53. Detaram HD, Joachim N, Liew G, Van Vu K, Burlutsky G, Mitchell P, et al. Smoking and treatment outcomes of neovascular age-related macular degeneration over 12 months. British Journal of Ophthalmology. 2020;104(7):893-8.
54. Vingerling JR, Hofman A, Grobbee DE, De Jong PT. Age-related macular degeneration and smoking: the Rotterdam Study. Archives of ophthalmology. 1996;114(10):1193-6.
55. Connolly E, Rhatigan M, O’Halloran AM, Muldrew KA, Chakravarthy U, Cahill M, et al. Prevalence of age-related macular degeneration associated genetic risk factors and 4-year progression data in the Irish population. British Journal of Ophthalmology. 2018;102(12):1691-5.
56. Lüdtke L, Jürgens C, Ittermann T, Völzke H, Tost F. Age-related macular degeneration and associated risk factors in the population-based study of health in pomerania (SHIP-Trend). Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2019;25:6383.
57. Choudhury F, Varma R, McKean-Cowdin R, Klein R, Azen SP, Group LALES. Risk factors for four-year incidence and progression of age-related macular degeneration: the Los Angeles Latino Eye Study. American journal of ophthalmology. 2011;152(3):385-95.
58. Thomas J, Mohammad S, Charnigo R, Baffi J, Abdel-Latif A, Ziada KM. Age-related macular degeneration and coronary artery disease in a VA population. Southern medical journal. 2015;108(8):502.
59. Wilde C, Poostchi A, Mehta R, MacNab H, Hillman J, Vernon S, et al. Prevalence of age-related macular degeneration in an elderly UK Caucasian population—The Bridlington eye assessment project: a cross-sectional study. Eye. 2017;31(7):1042-50.
60. Wang JJ, Klein R, Smith W, Klein BE, Tomany S, Mitchell P. Cataract surgery and the 5-year incidence of late-stage age-related maculopathy: Pooled findings from the Beaver Dam and Blue Mountains eye studie. Ophthalmology. 2003;110(10):1960-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Inara Ismayilova, Andrii Korol, Neilya Aldasheva (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.